Article Text

Download PDFPDF
Variation in management of women with threatened preterm labour

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors SJS conceived the study and drafted the manuscript. All authors contributed to the design of survey and testing of survey, interpretation of results and commented on the manuscript.

  • Competing interests AHS has consultancy arrangements with Hologic (who market Fetal Fibronectin), Alere (who market Actim Partus), GlaxoSmithKline and ObsEva. Quiagen (who market Partosure) provide tests for research. JEN is Chair of the NICE Guideline Development Group on Preterm Labour and Birth. The views expressed here are not those of the GDG. JEN is also on a Data Monitoring Committee for Glaxo Smith Kline. MC has contributed to educational talks for HOLOGIC and attended meetings sponsored by HOLOGIC.

  • Provenance and peer review Not commissioned; internally peer reviewed.